TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional)
TSRI-147.2 Con 2

St. fin res About ation of:

Charles G. Cochrane and Susan D. Revak

Application No

08/419,824

CADEMINI

April 11, 1995

For:

PULMONARY SURFACTANT PROTEINS AND RELATED POLYPEPTIDES

The owner, <u>The Scripps Research Institute</u>, of <u>100</u> percent interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent Nos. <u>5,260,273 and 5,407,914</u>. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. () For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. (x) The undersigned is an attorney of record.

Date

Talivaldis Cepuritis (Reg. No. 20,818)

Typed or printed name and title if applicable

- (x) Terminal disclaimer fee under 37 CFR 1.20(d) included.
 - (x) PTO suggested wording for terminal disclaimer was

(x) unchanged, () changed (if changed, an explanation should be supplied).

13

DATE: 12-1-97	APPL. S.N.: 08/4/9824
TO EXAMINER:	ART UNIT:
	/8 MAILROOM DATE 9-15-97
AFTER FINAL YES NO NUMBER INSTRUCTIONS: I have reviewed the submitted T.D. with the reappropriate form paragraphs identified by this informal memo in a disagree with my analysis or have questions at all about the acceptaminer. THIS MEMO IS AN INFORMAL, INTERNAL MEMO SHOULD A COPY BE IN LEFT IN FILE.	esults as set forth below. If you agree, please use the your next office action to notify applicant about the T.D. If you eptablity of the T.D., please see me or our Special Program
(4 The T.D. is PROPER and has been recorded. (See 14.23).	•
[] The T.D. is NOT PROPER and has not been accepted for the	the reason(s) checked below. (See 14.24).
[] The recording fee of \$ has not been submitted n to a deposit account. (See 14.26.07)	or is there any pre authorization in the application file to charge
[] Application Examiner has not processed T.D. fee. (See fee	authorization).
[] The T.D. does not satisfy Rule 321(b)(3) in that the person (and/or the extent of the interest of the business entity represente 14.26.01).	who has signed the T.D. has not stated his/her interest ed by the signature) in the application/patent. (See 14.26 and
[] The T.D. lacks the enforceable only during the common owe Rule 321(c). (See 14.27, 14.27.01).	rship clause needed to overcome a double patenting rejection,
[] It is directed to a particular claims(s), which is not acceptable term of the entire patent to be granted. MPEP 1490. (See 14.26)	e since "the disclaimer must be of a terminal portion of the , 14.26.02).
[] The person who signed the terminal disclaimer: [] has failed to state his/her capacity to sign for the bu [] is not recognized as an officer of the assignee, (Sec	e 14.29 and possibly 14.29.01).
[] No documentary evidence of a chain of title from the original is and frame specified as to where such evidence is recorded in the documentary evidence or the specifying of the reel and frame may applicant. (See 14.30).	office, 37 CFR 3.73(b), (See 1140 O.G. 72), NOTE: This
[] No "statement" specifying that the evidentiary documents hav knowledge and belief the title is in the assignee seeking to take ac	e been reviewed and that, to the best of the assignee's tion. 37 CFR 3.73(b). (See 1140 O.G. 72) (See 14.31).
[] The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if T	D is not signed by all the owners.
[] Attorney not of record in oath/decl. or a seperate paper filed a	ppointing a new or associate attorney. (See 14.29.01).
[] The serial number of the application (or the number of the pat missing or incorrect. (See 14.32).	ent) which forms the basis for the double patenting is
[] The serial number of this application (or the number of the pat or incorrect. (See 14.26, 14.26.04 or 14.26.05).	ent in reexam or reissue case(s) being disclaimed is missing
[] The period disclaimed is incorrect or not specified. (See 14.27	7, 14.27.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)
[] Other:	
[] Suggestion to request refund of \$ (See 14.35, 1	
[] EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR MAY BE FAXED IN TO THE GROUP	R ALLOWANCE ANY OF THE ABOVE INFORMALTIES
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:	
 Sample of a TD over a pending application and assignee Certificate (See 14.37). Sample of a TD over a prior patent and assignee Certificate (See 14.38). Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39) 	